96837-44-4

Upstream product

• 95530-58-8 (R)-4-isopropyloxazolidin-2-one 
• 645-45-4 hydrocinnamic acid chloride 
• 501-52-0 3-Phenylpropionic acid 
• 17016-83-0 4-isopropyloxazolidin-2-one 
• 109-72-8 n-butyllithium 

Downstream Products

• 96860-54-7 [(1S,3S)-3-Benzyl-1-isobutyl-4-((R)-4-isopropyl-2-oxo-oxazolidin-3-yl)-2,4-dioxo-butyl]-carbamic acid tert-butyl ester 
• 215797-98-1 (4R)-((2R,3R,4S)-2-benzyl-3-hydroxy-4-benzyloxypentanoyl)-4-isopropyloxazolidin-2-one 
• 96860-55-8 [(1S,2S,3S)-3-Benzyl-2-hydroxy-1-isobutyl-4-((R)-4-isopropyl-2-oxo-oxazolidin-3-yl)-4-oxo-butyl]-carbamic acid tert-butyl ester 
• 207444-45-9 (R)-3-((S)-2-Hydroxymethyl-3-phenyl-propionyl)-4-isopropyl-oxazolidin-2-one 
• 168134-74-5 Acetic acid (S)-2-benzyl-3-((R)-4-isopropyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl ester 
• 167173-85-5 (3S,6S,7R,8R)-8-benzyl-3-{[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]amino}-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl2-methylpropanoate 
• 215798-00-8 (3S,6S,7R,8R)-8-benzyl-3-[(tert-butoxycarbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate 
• 215798-16-6 isobutyric acid (3R,6S,7R,8R)-8-benzyl-3-tert-butoxycarbonylamino-6-methyl-4,9-dioxo-[1,5]dioxonane-7-yl ester 
• 210300-16-6 (2R,3R,4S)-2-Benzyl-4-((R)-2-tert-butoxycarbonylamino-3-hydroxy-propionyloxy)-3-(tert-butyl-dimethyl-silanyloxy)-pentanoic acid 
• 210300-12-2 (2R,3R,4S)-2-benzyl-4-((2S)-2-tert-butoxycarbonylamino-3-hydroxypropionyloxy)-3-(tert-butyldimethylsilanyloxy)-pentanoic acid 
• 210300-13-3 [(3S,7R,8R,9S)-7-benzyl-8-(tert-butyldimethylsilanyloxy)-9-methyl-2,6-dioxo-[1,5]dioxonane-3-yl]-carbamic acid tert-butyl ester 
• 210300-17-7 [(3R,7R,8R,9S)-7-benzyl-8-(tert-butyldimethylsilanyloxy)-9-methyl-2,6-dioxo-[1,5]dioxonane-3-yl]-carbamic acid tert-butyl ester 
• 215798-09-7 (2R,3R,4S)-2-benzyl-3-(tert-butyldimethylsilanyloxy)-4-(4-methoxybenzyloxy)-pentanoic acid benzyl ester 
• 215798-10-0 ((3S,7R,8R,9S)-7-benzyl-8-hydroxy-9-methyl-2,6-dioxo-[1,5]dioxonane-3-yl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Diastereoselective Electrophilic Trifluoromethylthiolation of Chiral Oxazolidinones: Access to Enantiopure α-SCF3 Alcohols

Lithium imide enolates featuring Evans’ chiral oxazolidinone auxiliary were involved in diastereoselective α-trifluoromethylthiolation with electrophilic SCF3 donors. Diastereopure products were isolated and converted to enantiopure α-SCF3 alcohols without racemisation. (Figure presented.).

A convenient and practical method for N-acylation of 2 oxazolidinone chiral auxiliaries with acids

A one-pot, convenient and practical method for N-acylation of 2- oxazolidinone chiral auxiliaries directly with acids in the presence of pivaloyl chloride and triethylamine is described.

Enantioselective total synthesis of the antifungal dilactone, UK-2A: The determination of the relative and absolute configurations

The synthesis of the antifungal dilactone, UK-2A, is described. In addition to providing a workable synthetic route to this potent antifungal antibiotic, this has allowed us to determine the assignment of the relative and absolute configurations in the nine-membered ring.

Total synthesis of the antifungal dilactones UK-2A and UK-3A: The determination of their relative and absolute configurations, analog synthesis and antifungal activities

The synthesis of the antifungal dilactones, UK-2A and UK-3A, is described. In addition to providing a workable synthetic route to these potent antifungal antibiotics, this has allowed us to determine the assignment of the relative and absolute configurations in the nine-membered ring. Furthermore, UK-2A analogs were also synthesized and evaluated their antifungal activities and cytotoxic activities along with UK-2A, (2R, 3R, 4S, 7R)-UK-2A, UK-3A, (2R, 3R, 4S, 7R)-UK-3A, and antimycin A. The structural requirements for the selective cytotoxicity against yeasts and filamentous fungi will also be suggested.

A convenient synthesis of enantiopure paraconic acid- A key intermediate in the synthesis of A-factor

Enantiopure (S)-(-)-paraconic acid 2 has been synthesised by the stereospecific benzyloxymethylation of a titanium enolate derived from a homochiral oxazolidinone and dihydrocinnamoyl chloride.

RENIN-INHIBITORY OLIGOPEPTIDES, THEIR PREPARATION AND USE

Compounds of formula (I): STR1 A is a carbon-carbon bond or C 1-C 3 alkylene; B is imino group or C 1-C 2 alkylene; R 1 is C 1-C 4 alkyl, C 1-C 4 alkoxy, heterocyclic or optionally substituted amino; R 2 is optionally substituted phenyl or optionally substituted naphthyl; R 3 is thiazolyl, isoxazolyl or imidazolyl; R 4 is isopropyl or cyclohexyl; R 5 and R 6 are C. sub.1-C 4 alkyl, or, together with the carbon atom to which they are attached, C 3-C 7 cycloalkyl; R. sup.7 is hydrogen, optionally substituted C 1-C 6 alkyl group; and R 8 is hydrogen or C. sub.1-C 4 alkyl. These compounds have renin-inhibitory and, hence, hypotensive activities. The invention also provides a method for the treatment or prophylaxis of hypertension induced by failures in the renin-angiotensin system.

Renin inhibitors having all retro-inverted peptide bonds

Renin-inhibiting peptides of the formula STR1 in which X represents a group of the formula STR2 represents hydroxyl, alkoxy having up to 8 carbon atoms, benzyloxy or a group of the formula --NR4 R5, A, B, D and E are identical or different and in each case represent a direct bond, represent a radical of the formula STR3 in which Q1 denotes oxygen, sulphur or the methylene group represent a grouping of the formula STR4 m represents a number 0, 1 or 2, and L represents a group of the formula --CH2 NR2 R3 and physiologically acceptable salts thereof.

HETEROCYCLIC PEPTIDE RENIN INHIBITORS

A renin inhibiting compound of the formula STR1 wherein X is N, O or CH; R 1 is absent or a functional group; A and L are independently selected from absent, C=O, SO 2 and CH 2 ; D is C=O, SO. sub.2 or CH 2 ; Y is N or CH; R 2 is hydrogen, loweralkyl or substituted alkyl; Z is a functional group; R 3 is loweralkyl or substituted alkyl; n is 0 or 1; and T is a mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Peptidyl difluorodiol renin inhibitors

A renin inhibiting compound of the formula: wherein A is a functional group; W is (1)-C(O)-,(2)-CH(OH)-or(3)-N(R?)-wherein R? is hydrogen or loweralkyl; U is (1)-C(O)-,(2)-CH?-or(3)-N(R?)-wherein R? is hydrogen or lower alkyl, with the proviso that when W is-CH(OH)-then U is-CH?-and with the proviso that U is-C(O)-or-CH?-when W is-N(R?)-; V is (1)-CH-,(2)-C(OH)-or(3)-C(halogen)-with the proviso that v is-CH--when U is-N(R?)-; Q is-CH(R?)-or-C(=CHR1a)-wherein R? is (1) loweralkyl,(2) cycloalkylalkyl,(3) arylalkyl,(4) (heterocyclic) alkyl,(5) 1-benzyloxyethyl,(6) phenoxy,(7) thiophenoxy or(8) anilino, provided that B is-CH?-or-CH(OH)-or A is hydrogen when R? is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R? is a functional group; R? is (1) loweralkyl,(2) cycloalkylmethyl or(3) benzyl; R? is-CH(OH)-or-C(O)-; R? is-CH(OH)-or-C(O)-; and Z is (1) lower alkyl,(2) aryl,(3) arylalkyl,(4) cycloalkyl,(5) cycloalkylalkyl,(6) heterocyclic or(7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 where A is a substituent; W is CO or CHOH and U is CH2 or NR2 wherein R2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is Ch2 ; R1 is loweralkyl, cycloalkyl methyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, 1-bezyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)loweralkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R4 is substituted hydroxyalkyamino.